[18F]AlF-NOTA-pentixather PET/CT in Patients With Suspected Primary Hyperaldosteronism
Clinical Study of Chemokine Receptor 4 (CXCR4)-Mediated Precision Targeting of 18F for the Diagnosis of Aldosteronism in Primary Aldosteronism
This study is testing a special imaging technique to see if it can help identify primary hyperaldosteronism in patients who might have this condition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Sichuan Provincial People's Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT05815069 on ClinicalTrials.gov |
What this trial studies
Processing failed - manual review needed
Who should consider this trial
Good fit: Unknown
Not a fit: Unknown
Why it matters
Potential benefit: Unknown
How similar studies have performed: Unknown
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Persistent hypertension or refractory hypertension (blood pressure \>140/90 mmHg with a combination of three antihypertensive drugs, including diuretics) with hypokalemia of blood pressure \>160/100 mmHg. * Uncontrollable hypokalemia with or without hypertension. Persistent hypertension or refractory hypertension with blood pressure \>160/100 mmHg and aldosterone-renin ratio (ARR) ≥30 (ng/dl)/(ng/ml/h). * Positive captopril test (≤30% decrease in plasma aldosterone level after captopril administration) is a sufficient but not mandatory condition. * Patients with CT showing unilateral or bilateral adrenal nodules with well-defined borders but normal serum potassium and ARR \<30 (ng/dl)/(ng/ml/h) were also included in the study. Exclusion Criteria: * Female patients who are pregnant (or intend to become pregnant within six months), breastfeeding, or unwilling to use contraception. * Abnormal cardiopulmonary function or mental status, unable to tolerate prone for 20 minutes. * Refusal to sign an informed consent form or inability or unwillingness to comply with the investigator-approved study protocol. * Other conditions deemed by the investigator to be inappropriate for participation in this study.
Where this trial is running
Chengdu, Sichuan
- Sichuan Academy of Medical Sciences.Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Wei Zhang, Ph.D
- Email: zhangwscd@uestc.edu.cn
- Phone: 86+02887393368
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions
Aldosterone-Producing Adenoma
Last reviewed 2026-06-13 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.